Pilocarpine

Drug Profile

Pilocarpine

Alternative Names: KSS-694; Salagen Granules; Salagen Tab.

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MGI Pharma
  • Developer Eisai Co Ltd; Kissei Pharmaceutical; Pfizer
  • Class Alkaloids; Antiglaucomas; Furans; Imidazoles; Miotics; Small molecules
  • Mechanism of Action Muscarinic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Xerostomia

Most Recent Events

  • 17 Jul 2017 Merus Labs has been acquired and merged into Norgine
  • 22 May 2015 Merus Labs enters into an agreement with Novartis Pharma for manufacturing and commercialisation of pilocarpine in Europe
  • 12 Dec 2014 Launched for Xerostomia in Japan (PO, Granules)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top